We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Meta‐analysis of arbidol versus lopinavir/ritonavir in the treatment of coronavirus disease 2019.
- Authors
Yu, Miao; Wang, Deng‐Chao; Li, Sheng; Lei, Yue‐Hua; Wei, Jian; Huang, Li‐Yan
- Abstract
Objectives: To systematically evaluate the efficacy and safety of arbidol and lopinavir/ritonavir (LPV/r) in the treatment of coronavirus disease 2019 (COVID‐19) using a meta‐analysis method. Methods: The China Knowledge Network, VIP database, WanFang database PubMed database, Embase database, and Cochrane Library were searched for a collection of comparative studies on arbidol and lopinavir/ritonavir in the treatment of COVID‐19. Meta‐analysis was used to evaluate the efficacy and safety of Arbidol and lopinavir/ritonavir in the treatment of COVID‐19. Results: The results of the systematic review indicated that Arbidol had a higher positive‐to‐negative conversion rate of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) nucleic acid on Day 7 (p = 0.03), a higher positive‐to‐negative conversion rate of SARS‐CoV‐2 nucleic acid on Day 14 (p = 0.006), a higher improvement rate of chest computed tomography on Day 14 (p = 0.02), a lower incidence of adverse reactions (p = 0.002) and lower rate of mortality (p = 0.007). There was no difference in the rate of cough disappearance on Day 14 (p = 0.24) or the rate of severe/critical illness (p = 0.07) between the two groups. Conclusions: Arbidol may be superior to lopinavir/ritonavir in the treatment of COVID‐19. However, due to the small number of included studies and the number of patients, high‐quality multicenter large‐sample randomized double‐blind controlled trials are still needed for verification.
- Subjects
CORONAVIRUS disease treatment; CORONAVIRUS diseases; COVID-19; SARS-CoV-2; COVID-19 treatment; RITONAVIR
- Publication
Journal of Medical Virology, 2022, Vol 94, Issue 4, p1513
- ISSN
0146-6615
- Publication type
Article
- DOI
10.1002/jmv.27481